Not a single patient who received standard therapy had locoregional recurrence during the first 2 years of follow-up. Overall ...

Unlike other gastrointestinal cancers, anal cancer has a lower tendency to metastasize, and most patients are diagnosed with locoregional disease (stages I–III). Treatments for this cancer tend ...

Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with ...